Aripiprazole (Abilify Maintena) vs Aripiprazole lauroxil (Aristada)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2/D3 and serotonin 5-HT1A receptor · full Schizophrenia pipeline
Aripiprazole (Abilify Maintena)
Marketed by Otsuka Holdings and partners
NCT00706654 · Phase 3 · completed
This was a randomized, double-blind, active-controlled trial with 662 randomized maintenance-phase participants, including 265 assigned to depot 300/400 mg and 266 to oral aripiprazole. The primary clinical relapse endpoint was met: depot treatment was non-inferior to oral aripiprazole, with a difference of -0.64 percentage points and a 95% confidence interval of -5.26 to 3.99, below the prespecified 11.5% margin.
Reported efficacy
Mean change from baseline to endpoint(10th week)in PANSS Total Score. (1st,2nd,4th,6th,8th,10th,12th week): LS mean change from baseline to Week 10 in PANSS Total Score: -33.6 (aripiprazole once-monthly, AOM) vs -34.8 (oral aripiprazole); difference -1.2 (95% CI: -4.1, 1.7), within the pre-defined non-inferiority margin (met)
Result source: NCT03172871
Aripiprazole lauroxil (Aristada)
Marketed by Alkermes plc
NCT01469039 · Phase 3 · completed
The trial was randomized, quadruple-blinded, and placebo-controlled, with 623 participants assigned to aripiprazole lauroxil 441 mg, 882 mg, or placebo. Its primary clinical symptom endpoint, change in PANSS total score at day 85, was significantly better with both active doses than with placebo (p<0.001 for each comparison).
Reported efficacy
The Change From Baseline at Day 85 in Positive and Negative Syndrome Scale (PANSS) Total Score (Data collected from baseline to day 85): The Change From Baseline at Day 85 in Positive and Negative Syndrome Scale (PANSS) Total Score (Data collected from baseline to day 85): Aripiprazole Lauroxil 441 mg -20.9 units on a scale (Standard Error 1.39) | Aripiprazole Lauroxil 882 mg -21.8 units on a scale (Standard Error 1.35) vs Placebo -9.8 units on a scale (Standard Error 1.39) (met)
Result source: NCT01469039
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Aripiprazole (Abilify Maintena) | Aripiprazole lauroxil (Aristada) |
|---|---|---|
| PANSS total, change | -26.8 vs -11.7−15.1 vs placeboNCT016635326 other results
| -21.8 vs -9.8−12 vs placeboNCT014690391 other result
|
| CGI-S, change | -1.4 vs -0.6−0.8 vs placeboNCT016635326 other results
| -0.5 vs -0.9+0.4 vs placeboNCT016264562 other results
|
| PANSS response | 37% vs 14.3%+22.7 vs placeboNCT01663532 | —Not reported |
| PSP, change | 12.3 vs 5.2+7.1 vs placeboNCT01663532 | —Not reported |
| Relapse (% of patients) | 10% vs 39.6%−29.6 vs placeboNCT00705783 | —Not reported |
PANSS total, change
- Aripiprazole (Abilify Maintena)
- -26.8 vs -11.7−15.1 vs placeboNCT01663532
6 other results
- -23.7 vs -9.7 NCT01663532
- -21.5 vs -10.3 NCT01663532
- -19 vs -9.8 NCT01663532
- -15.2 vs -8.3 NCT01663532
- -8.9 vs -5 NCT01663532
- -33.6 vs -34.8 NCT03172871
- Aripiprazole lauroxil (Aristada)
- -21.8 vs -9.8−12 vs placeboNCT01469039
1 other result
- -20.9 vs -9.8 NCT01469039
CGI-S, change
- Aripiprazole (Abilify Maintena)
- -1.4 vs -0.6−0.8 vs placeboNCT01663532
6 other results
- -1.3 vs -0.6 NCT01663532
- -1.2 vs -0.5 NCT01663532
- -1 vs -0.4 NCT01663532
- -0.8 vs -0.4 NCT01663532
- -0.4 vs -0.2 NCT01663532
- -0.8 vs -0.5 NCT01795547
- Aripiprazole lauroxil (Aristada)
- -0.5 vs -0.9+0.4 vs placeboNCT01626456
2 other results
- -0.3 vs -0.9 NCT01626456
- -0.2 vs -0.9 NCT01626456
PANSS response
- Aripiprazole (Abilify Maintena)
- 37% vs 14.3%+22.7 vs placeboNCT01663532
- Aripiprazole lauroxil (Aristada)
- —Not reported
PSP, change
- Aripiprazole (Abilify Maintena)
- 12.3 vs 5.2+7.1 vs placeboNCT01663532
- Aripiprazole lauroxil (Aristada)
- —Not reported
Relapse (% of patients)
- Aripiprazole (Abilify Maintena)
- 10% vs 39.6%−29.6 vs placeboNCT00705783
- Aripiprazole lauroxil (Aristada)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety
Coverage. Aripiprazole (Abilify Maintena): 7 of 7 rows · Aripiprazole lauroxil (Aristada): 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Aripiprazole (Abilify Maintena) Rows use multiple source trials | Aripiprazole lauroxil (Aristada) Rows use multiple source trials |
|---|---|---|
| CGI-S absolute change · score No placebo or comparator arm | -0.24 score @ 52wk400/300 mg IM Depota,b,c,d NCT00731549 · Phase 3 · registry result, not featured evidence | -0.2 scorea,b,c,d NCT02634320 · Phase 4 · registry result, not featured evidence 2 other source trials-0.1 scoreHigh NCT01895452 · Phase 3 · registry result, not featured evidence -0.1 scoreLow NCT01895452 · Phase 3 · registry result, not featured evidence |
| PANSS Total absolute change · score No placebo or comparator arm | -3.55 score @ 52wk400/300 mg IM Depotb,c,d NCT00731549 · Phase 3 · registry result, not featured evidence | -0.9 scoreHighe,b,c,d NCT01895452 · Phase 3 · registry result, not featured evidence show 1 more dose-0.7 scoreLow NCT01895452 · Phase 3 · registry result, not featured evidence |
| QLS Total absolute change · score No placebo or comparator arm | 2.32 score @ 24wka,b,c,d NCT01959035 · Phase 3 · registry result, not featured evidence | 0.4 scorea,b,c,d NCT02634320 · Phase 4 · registry result, not featured evidence |
| Dropout rate | —300 or 400 mgf NCT00706654 · Phase 3 show 13 more results—25 or 50 mg NCT00706654 · Phase 3 —Aripiprazole Depot NCT00705783 · Phase 3 · monotherapy —Aripiprazole Depot - Depot Mainten NCT00705783 · Phase 3 · monotherapy 44%400/300 mg NCT01663532 · Phase 3 26.1% NCT02360319 · Phase 4 · registry result, not featured evidence 12.5% NCT01959035 · Phase 3 · registry result, not featured evidence 32.4% NCT01795547 · Phase 3 · registry result, not featured evidence 39.2%400/300 mg NCT01683058 · Phase 3 · registry result, not featured evidence 20.6%400/300 mg IM Depot NCT00731549 · Phase 3 · registry result, not featured evidence —400 mg NCT01909466 · Phase 1 · registry result, not featured evidence 11.1%400 mg NCT01646827 · Phase 1 · registry result, not featured evidence 26.3%400 mg NCT01646827 · Phase 1 · registry result, not featured evidence 6.7%400mg NCT01552772 · Phase 1 · registry result, not featured evidence | 35.1%882 mgg NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 6 more results37.2%441 mg NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3 31.8%ALKS 9072, High NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3 31.8%ALKS 9072, Low NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3 31.4% NCT02634320 · Phase 4 · registry result, not featured evidence 12.4%High NCT01895452 · Phase 3 · registry result, not featured evidence 6.2%Low NCT01895452 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | —300 or 400 mgf NCT00706654 · Phase 3 show 13 more results—25 or 50 mg NCT00706654 · Phase 3 —Aripiprazole Depot NCT00705783 · Phase 3 · monotherapy —Aripiprazole Depot - Depot Mainten NCT00705783 · Phase 3 · monotherapy 4.2%400/300 mg NCT01663532 · Phase 3 — NCT02360319 · Phase 4 · registry result, not featured evidence 5.7% NCT01959035 · Phase 3 · registry result, not featured evidence 10.8% NCT01795547 · Phase 3 · registry result, not featured evidence 8.1%400/300 mg NCT01683058 · Phase 3 · registry result, not featured evidence 2.9%400/300 mg IM Depot NCT00731549 · Phase 3 · registry result, not featured evidence —400 mg NCT01909466 · Phase 1 · registry result, not featured evidence —400 mg NCT01646827 · Phase 1 · registry result, not featured evidence —400 mg NCT01646827 · Phase 1 · registry result, not featured evidence 1.7%400mg NCT01552772 · Phase 1 · registry result, not featured evidence | —882 mgg NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 6 more results—441 mg NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3 7.3%ALKS 9072, High NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3 1.8%ALKS 9072, Low NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3 3.9% NCT02634320 · Phase 4 · registry result, not featured evidence 1.8%High NCT01895452 · Phase 3 · registry result, not featured evidence 1.5%Low NCT01895452 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 5.7%300 or 400 mgf NCT00706654 · Phase 3 show 13 more results8.4%25 or 50 mg NCT00706654 · Phase 3 —Aripiprazole Depot NCT00705783 · Phase 3 · monotherapy 4.1%Aripiprazole Depot - Depot Mainten NCT00705783 · Phase 3 · monotherapy 4.8%400/300 mg NCT01663532 · Phase 3 29.1% NCT02360319 · Phase 4 · registry result, not featured evidence 3.4% NCT01959035 · Phase 3 · registry result, not featured evidence 8.3% NCT01795547 · Phase 3 · registry result, not featured evidence 6.8%400/300 mg NCT01683058 · Phase 3 · registry result, not featured evidence 8.8%400/300 mg IM Depot NCT00731549 · Phase 3 · registry result, not featured evidence 2.9%400 mg NCT01909466 · Phase 1 · registry result, not featured evidence 0%400 mg NCT01646827 · Phase 1 · registry result, not featured evidence 0%400 mg NCT01646827 · Phase 1 · registry result, not featured evidence 1.7%400mg NCT01552772 · Phase 1 · registry result, not featured evidence | 1.9%882 mgg NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 6 more results1.4%441 mg NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3 4.1%ALKS 9072, High NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3 0%ALKS 9072, Low NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3 9.8% NCT02634320 · Phase 4 · registry result, not featured evidence 1.8%High NCT01895452 · Phase 3 · registry result, not featured evidence 0%Low NCT01895452 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | show 12 more resultsinsomnia 10% (placebo 9%) weight increased 9.7% (placebo 9.7%) anxiety 5.9% (placebo 7.5%) NCT00705783 · Phase 3 · monotherapy 400/300 mg weight increased 16.8% (placebo 7%) headache 14.4% (placebo 16.3%) akathisia 11.4% (placebo 3.5%) NCT01663532 · Phase 3 weight gain 14.4% anxiety 12.2% depression 10.4% NCT02360319 · Phase 4 · registry result, not featured evidence weight increased 6.8% NCT01959035 · Phase 3 · registry result, not featured evidence accidental overdose 20.8% insomnia 11.8% weight increased 9% NCT01795547 · Phase 3 · registry result, not featured evidence 400/300 mg weight increased 29.7% akathisia 12.2% headache 8.1% NCT01683058 · Phase 3 · registry result, not featured evidence 400/300 mg IM Depot headache 7.6% nasopharyngitis 7% anxiety 6.8% NCT00731549 · Phase 3 · registry result, not featured evidence 400 mg injection site pain 27.5% weight increased 12.3% headache 11.6% NCT01909466 · Phase 1 · registry result, not featured evidence 400 mg injection site pain 35.3% headache 23.5% akathisia 17.6% NCT01646827 · Phase 1 · registry result, not featured evidence 400 mg injection site pain 27.8% headache 22.2% akathisia 16.7% NCT01646827 · Phase 1 · registry result, not featured evidence 400mg injection site pain 6.7% toothache 6.7% blood creatine phosphokinase increased 5% NCT01552772 · Phase 1 · registry result, not featured evidence | 882 mgg insomnia 12% (placebo 11.6%) akathisia 11.1% (placebo 4.3%) headache 8.7% (placebo 8.2%) NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 6 more results441 mg akathisia 11.6% (placebo 4.3%) insomnia 9.7% (placebo 11.6%) headache 8.2% (placebo 8.2%) NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3 insomnia 10.1% weight increased 4.6% headache 3% NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3 headache 6.4% weight increased 6.4% insomnia 2.7% NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3 anxiety 5.9% NCT02634320 · Phase 4 · registry result, not featured evidence High insomnia 7.1% nasopharyngitis 4% diarrhoea 3.1% NCT01895452 · Phase 3 · registry result, not featured evidence Low diarrhoea 6.2% nasopharyngitis 6.2% toothache 6.2% NCT01895452 · Phase 3 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 3 versus Phase 4.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dThe assessment timepoint is not available for both results.
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fPopulation comparability has not been reviewed for these studies.
- gPopulation comparability has not been reviewed for 3 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Aripiprazole (Abilify Maintena)
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 31 further endpoints in the CSV export.
Aripiprazole lauroxil (Aristada)
show 2 more results
show 2 more results
show 2 more results
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aripiprazole (Abilify Maintena)'s landscape · Aripiprazole lauroxil (Aristada)'s landscape